[{"orgOrder":0,"company":"SparingVision","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"SparingVision \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"SparingVision \/ Undisclosed"},{"orgOrder":0,"company":"Pfenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Pfenex","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfenex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfenex \/ Not Applicable"},{"orgOrder":0,"company":"ProLynx","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"PTH(1-34)","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"ProLynx \/ National Institute of Health","highestDevelopmentStatusID":"4","companyTruncated":"ProLynx \/ National Institute of Health"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antares Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antares Pharma \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Grunenthal \/ Teva Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Grunenthal \/ Teva Pharmaceutical"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2020","type":"Series E Financing","leadProduct":"Teriparatide","moa":"PTH 34 N-terminal amino acid","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.070000000000000007,"dosageForm":"Enteric-coated Capsule","sponsorNew":"Rani Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Theramex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Pen","sponsorNew":"Theramex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theramex \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH 34 N-terminal amino acid","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH1R","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Accord healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Accord healthcare \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTHR","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTHR","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Parathyroid Hormone (1-34)","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Avenue Venture Opportunities Fund"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Parathyroid Hormone (1-34)","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"U.S. Food and Drug Administration","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ U.S. Food and Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ U.S. Food and Drug Administration"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Parathyroid Hormone (1-34)","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Extend Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Parathyroid Hormone (1-34)","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Extend Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Extend Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Extend Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Ambio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Ambio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ambio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ambio \/ Not Applicable"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Ambio","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apotex Fermentation Inc. \/ Ambio","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fermentation Inc. \/ Ambio"}]

Find Clinical Drug Pipeline Developments & Deals for Teriparatide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Teriparatide

                          Therapeutic Area : Musculoskeletal

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : USFDA approved biosimilar, Kauliv (human teriparatide hormone), for the treatment of both men and postmenopausal women with osteoporosis who are at high risk for having broken bones or fractures.

                          Brand Name : Kauliv

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          November 14, 2022

                          Lead Product(s) : Teriparatide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Strides Pharma Science

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : EB613 (teriparatide) is the first and most advanced oral, daily tablet formulation of synthetic hPTH (1-34), which is being evaluated for the treatment of osteoporosis.

                          Brand Name : EB613

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          March 26, 2024

                          Lead Product(s) : Teriparatide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Forteo-Generic (teriparatide) is a parathyroid hormone analog, (PTH 1-34), which is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

                          Brand Name : Forteo-Generic

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          December 01, 2023

                          Lead Product(s) : Teriparatide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : EB613 (teriparatide) is first-in-class oral PTH(1-34) peptide biosimilar, which is being evaluated in phase 2 clinical trials for the treatment of Osteoporosis.

                          Brand Name : EB613

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          November 29, 2023

                          Lead Product(s) : Teriparatide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Teriparatide Injection, a single-patient-use pre-filled pen and a parathyroid hormone analog, is used for the treatment of osteoporosis in the United States.

                          Brand Name : Teriparatide-Generic

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          November 21, 2023

                          Lead Product(s) : Teriparatide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved

                          Sponsor : Ambio

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Teva got approval for generic version of Forteo (teriparatide injection) in the United States, which is indicated to treat osteoporosis among certain women and men.

                          Brand Name : Forteo-Generic

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          November 17, 2023

                          Lead Product(s) : Teriparatide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : EB613 (oral PTH (1-34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for osteoporosis.

                          Brand Name : EB613

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          November 09, 2023

                          Lead Product(s) : Teriparatide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : EXT608 is a long-acting derivative of parathyroid hormone (PTH). Developed using ExtendBio’s D-VITylation® platform, the compound is fully active at the PTH receptor upon injection for the treatment of hypoparathyroidism.

                          Brand Name : EXT608

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 11, 2023

                          Lead Product(s) : Teriparatide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : EB613 is the first oral, once daily mini tablet presentation of synthetic hPTH (1-34), (teriparatide), consisting of the exact same 34 amino acid sequence as daily subcutaneous teriparatide injection, Forteo®, which requires daily SC injections.

                          Brand Name : EB613

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          April 03, 2023

                          Lead Product(s) : Teriparatide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : EB613 (teriparatide) is an oral, daily tablet which stimulates new bone formation on trabecular and cortical bone surfaces by preferential stimulation of osteoblastic activity over osteoclastic activity. It is being investigated for post-menopausal osteo...

                          Brand Name : EB613

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          February 15, 2023

                          Lead Product(s) : Teriparatide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank